AU732820B2 — High-affinity oligonucleotide ligands to growth factors
Assigned to Nexstar Pharmaceuticals Inc · Expires 2001-05-03 · 25y expired
What this patent protects
Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF², PDGF and hKGF. Included in the invention are specific RNA and ssDNA ligands to TGF²1 and PDGF identified by the SELEX method. Also included in the invention are specific RN…
USPTO Abstract
Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF², PDGF and hKGF. Included in the invention are specific RNA and ssDNA ligands to TGF²1 and PDGF identified by the SELEX method. Also included in the invention are specific RNA ligands to hKGF identified by the SELEX method. Further included are RNA ligands that inhibit the interaction of TGF²1 and hKGF with their receptors and DNA ligands that inhibit the interaction of PDGF with its receptor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.